No profile data available.
Pyxis Oncology, Inc. (PYXS) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 56 full-time employees.
It reported revenue of $13.86 million for fiscal year 2025, down 14.2% from fiscal year 2024, and net income of -$79.62 million. Its market capitalization was $242.50 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Pyxis Oncology reported $13.86 million in revenue for fiscal year 2025, down 14.2% from $16.15 million in fiscal year 2024.
$242.50 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Fate Therapeutics, Inc. (FATE), Zentalis Pharmaceuticals, Inc. (ZNTL), Immuneering Corporation (IMRX), MacroGenics, Inc. (MGNX).